COGT Latest Headlines

LifeSci Capital Sticks to Their Buy Rating for Cogent Biosciences (COGT)

at www.tipranks.com (Sat, 21-Mar 10:57 AM)

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Ascendis Pharma (ASND)

at www.tipranks.com (Tue, 17-Mar 12:40 PM)

Wedbush Keeps Their Buy Rating on Cogent Biosciences (COGT)

at www.tipranks.com (Tue, 17-Mar 9:16 AM)

FDA Accepts Cogent’s Bezuclastinib NDA for NonAdvanced Systemic Mastocytosis: Trial Results Show Sustained Benefits

Market Chameleon (Mon, 16-Mar 8:37 AM)

Bezuclastinib Shows Durable 48-Week Benefits for NonAdvanced Systemic Mastocytosis—TSS Drops 32 Points, 99% See Tryptase Reduction

Market Chameleon (Mon, 2-Mar 9:17 AM)

Cogent Biosciences Targets Pivotal 2026 Milestones for Bezuclastinib, Bolstered by $900M Cash Position

Market Chameleon (Mon, 12-Jan 9:16 AM)